BRCA2 mutation and the risk of hematologic malignancy [8]

Michael J. Hall; Loretta Li; Peter H. Wiernik; Olufunmilayo I. Olopade

doi:10.1080/10428190500399193

BRCA2 mutation and the risk of hematologic malignancy [8]

Michael J. Hall, Loretta Li, Peter H. Wiernik, Olufunmilayo I. Olopade^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English (US)
Pages (from-to)	765-767
Number of pages	3
Journal	Leukemia and Lymphoma
Volume	47
Issue number	4
DOIs	https://doi.org/10.1080/10428190500399193
State	Published - Apr 2006

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428190500399193

Cite this

@article{785c86be79724c1191e0cf422cce0771,

title = "BRCA2 mutation and the risk of hematologic malignancy [8]",

author = "Hall, {Michael J.} and Loretta Li and Wiernik, {Peter H.} and Olopade, {Olufunmilayo I.}",

note = "Funding Information: We thank Dr. Stephen T. Reeders for discussion and assistance in manuscript preparation. X.-Z.C. is recipient of the International Human Frontier Science Program, Long-Term Fellowship. This work is supported by the Polycystic Kidney Research Foundation, NARSAD and Stanley Foundation (to P.M.V.), NIH (to J.Z., E.M.B., and M.A.H). and the St. Giles Foundation (to E.M.B.).",

year = "2006",

month = apr,

doi = "10.1080/10428190500399193",

language = "English (US)",

volume = "47",

pages = "765--767",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - BRCA2 mutation and the risk of hematologic malignancy [8]

AU - Hall, Michael J.

AU - Li, Loretta

AU - Wiernik, Peter H.

AU - Olopade, Olufunmilayo I.

N1 - Funding Information: We thank Dr. Stephen T. Reeders for discussion and assistance in manuscript preparation. X.-Z.C. is recipient of the International Human Frontier Science Program, Long-Term Fellowship. This work is supported by the Polycystic Kidney Research Foundation, NARSAD and Stanley Foundation (to P.M.V.), NIH (to J.Z., E.M.B., and M.A.H). and the St. Giles Foundation (to E.M.B.).

PY - 2006/4

Y1 - 2006/4

UR - http://www.scopus.com/inward/record.url?scp=33646765802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646765802&partnerID=8YFLogxK

U2 - 10.1080/10428190500399193

DO - 10.1080/10428190500399193

M3 - Letter

C2 - 16690535

AN - SCOPUS:33646765802

SN - 1042-8194

VL - 47

SP - 765

EP - 767

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 4

ER -

BRCA2 mutation and the risk of hematologic malignancy [8]

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this